Last updated: February 22, 2026
What is the marketed drug identified by NDC 00121-4776?
NDC 00121-4776 corresponds to Keytruda (pembrolizumab), a PD-1 immune checkpoint inhibitor used primarily in oncology for the treatment of metastatic or unresectable melanoma, non-small cell lung carcinoma, head and neck squamous cell carcinoma, and other cancers.
What is the current market size for Keytruda?
As of 2022, Keytruda holds the largest share among PD-1 inhibitors.
- Global sales: $13.16 billion (IQVIA, 2022).
- U.S. market share: ~65% of PD-1/PD-L1 class sales (EvaluatePharma, 2022).
- Year-over-year growth: approximately 12% from 2021 to 2022.
The drug's primary revenue drivers include approvals for multiple indications and expanded line labels, including first- and second-line therapies.
What are the key competitors and market dynamics?
Main competitors:
- Opdivo (nivolumab) from BMS.
- Libtayo (cemiplimab) from Regeneron.
- Tecentriq (atezolizumab) from Roche.
Market dynamics:
- Expanding indications increase overall sales.
- Combination therapies, especially Keytruda with chemotherapy or other immunotherapies, accelerate revenue potential.
- Biosimilar competition is limited, given the complexity of biologics and patent protections.
Patent landscape:
- Patent expiry for key patents scheduled from 2028–2030 in the U.S.
- Patent litigations may extend exclusivity in certain markets, delaying biosimilar entry.
What is the price structure of Keytruda?
U.S. retail price:
- Average wholesale price (AWP): approximately $12,500 per 100 mg vial.
- Typical treatment courses: 200 mg every 3 weeks, translating to $25,000 per dose and $312,500 annually per patient (per standard dosing guidelines).
Reimbursement:
- Commercial insurers reimburse at levels close to AWP minus negotiated discounts.
- Medicare Part B covers Keytruda with 80% coverage, influencing net revenue estimates.
International pricing:
- Prices vary; for example, in Europe, the list price ranges between €6,000–€10,000 per 200 mg dose, depending on the country and reimbursement policies.
What are the future price projections?
Short-term (2023–2025):
- Price stability expected due to patent protection and limited biosimilar competition.
- Slight discounts or value-based pricing agreements may lower net prices by 10–15% in some markets.
Medium-term (2026–2030):
- Potential price erosion begins prior to patent expiry, driven by:
- Biosimilar development and regulatory approvals.
- Value-based contracting models in payers’ negotiations.
- Cost reductions of approximately 20–30% anticipated if biosimilars enter the market, based on historical biologic price declines.
Long-term outlook:
- Patent expirations could reduce list prices by 50% or more, similar to trends seen with other biologics such as Herceptin and Rituxan.
- Market share distribution will shift, with biosimilars capturing a significant segment post-patent expiry.
What are the strategic implications?
- R&D investments focused on combination therapies and newer indications can sustain revenue growth amid impending biosimilar competition.
- Negotiation strategies with payers will heavily influence net pricing.
- Entry into emerging markets could extend cash flow, but pricing will be sensitive to local policies.
Summarized Data Table
| Aspect |
Current Data |
Future Projection |
| 2022 Global Sales |
$13.16 billion |
Stable through 2025; potential slow decline |
| List Price (U.S.) |
~$12,500 per 100 mg vial |
Stable; minor discounts to be applied |
| Patent Expiry |
2028–2030 (U.S.) |
Biosimilar entry anticipated post-2028 |
| Price Erosion Potential |
10–15% in 2023–2025 |
20–30% less post-silicon biosimilar market entry |
Key Takeaways
- Keytruda remains the market leader among PD-1 inhibitors.
- Revenue growth is driven by expanding indications, combination regimens, and market dominance.
- Prices are high, with stable near-term outlook; long-term, biosimilar competition will significantly impact pricing and market share.
- Navigating patent expiries, biosimilar development, and payer negotiations will be crucial for maintaining profitability.
FAQs
1. When will biosimilars for Keytruda enter the market?
Biosimilar approvals are expected post-patent expiry, likely around 2028 in the U.S. and Europe.
2. How much can prices decline upon biosimilar entry?
Historically, biosimilar introduction results in 50% or more list price reductions over 2–3 years.
3. Which indications contribute the most to Keytruda’s revenue?
Melanoma, non-small cell lung cancer, and head and neck cancers are primary revenue drivers.
4. Are there substantial regional price differences?
Yes. U.S. prices are higher; European and emerging markets have significantly lower list prices due to differing reimbursement structures.
5. How might combination therapies affect future revenue?
They expand indications and treatment options, potentially increasing overall sales despite price pressures.
References:
[1] IQVIA (2022). Pharmaceutical Market Reports.
[2] EvaluatePharma (2022). World Preview 2022.
[3] U.S. Food and Drug Administration (FDA). (2022). Drug Approvals and Labeling.
[4] European Medicines Agency (EMA). (2022). Product Data.
